Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

18 February 2021, London, UK: Advent Life Sciences, a leading transatlantic venture investor focused on building innovative life science companies in the UK, Europe and the US, announced today that it has closed two new funds with commitments totalling $215 million.

Read full release here